Pfizer’s Mixed Readout Places Doubt On Oral GLP-1 For Obesity

 
• By Joseph Haas

Twice-daily danuglipron reduced weight in a Phase IIb trial but with a poor side-effect profile and high discontinuation rates. Pfizer is working on a once-daily formulation it hopes will offer better tolerability.

Pfizer sign
Pfizer puts hopes for oral GLP-1 agonist on daily formulation work

More from Clinical Trials

More from R&D